Anti-GITR antibodies - Bristol-Myers Squibb

Drug Profile

Anti-GITR antibodies - Bristol-Myers Squibb

Alternative Names: Anti-AITR antibody; Anti-CD357 antibody; Anti-GITR-D antibody; Anti-TNFRSF18 antibody

Latest Information Update: 19 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 26 Feb 2016 Phase-I clinical trials in Cancer in USA (unspecified route) (Bristol-Myers Squibb website, March 2016)
  • 05 Jan 2016 Bristol-Myers Squibb has patent protection for Anti-GITR antibodies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top